Resonance Health Banks $733K R&D Refund While Turning a Profit in FY25
Resonance Health receives $732,851 R&D tax refund, boosting cash reserves
Resonance Health (ASX: RHT) has received a refund totalling $732,851 from the Australian Taxation Office, strengthening the medical imaging company’s cash position. The net payment relates to research and development activities conducted during FY2025.
The cash injection represents the difference between the company’s gross R&D tax incentive refund of $832,959 and income tax payable of $100,108. The tax payable component indicates underlying profitability during the financial year, whilst the refund provides non-dilutive funding to support ongoing product development.
The updated cash position will be disclosed in the company’s March 2026 Appendix 4C and Quarterly Activities Report.
Refund Breakdown:
- Gross R&D tax incentive: $832,959
- Less: Income tax payable: $100,108
- Net cash received: $732,851
When big ASX news breaks, our subscribers know first
What is the R&D Tax Incentive and why it matters for medtech investors
Australia’s R&D Tax Incentive program provides eligible companies with a percentage refund on qualifying research and development expenditure. This government support effectively reduces the cost of innovation, allowing healthcare technology firms to invest in product development whilst managing cash burn. Medical device and diagnostic companies like Resonance Health (ASX: RHT) frequently benefit from the scheme, as the development of regulatory-cleared software and AI-driven diagnostic tools requires substantial R&D investment.
For investors, recurring R&D refunds signal active product development and provide a visible cash flow benefit that extends operational runway without shareholder dilution.
Resonance Health’s R&D focus areas
The company maintains ISO 13485 certification for medical device design and manufacture, supporting its portfolio of regulatory-cleared Software-as-Medical Devices (SaMD) products. Current R&D activities centre on:
- FerriScan® and FerriSmart®: MRI-based liver iron concentration assessment tools, with FerriScan recognised as the global gold standard
- LiverSmart®: AI-trained multi-parametric device combining iron and fat assessment
- HepaFatScan® and HepaFatSmart®: Non-invasive liver fat assessment solutions
- MRI Liver Fibrosis Project: Development pipeline product targeting non-invasive fibrosis assessment
The ongoing R&D expenditure reflects continued investment in AI-driven diagnostic capabilities and pipeline expansion that could drive future revenue streams.
The next major ASX story will hit our subscribers first
Cash position and next reporting milestone
The refund adds directly to cash at bank, with the full updated cash position to be disclosed in Resonance Health’s March 2026 Appendix 4C and Quarterly Activities Report. Investors should monitor the upcoming quarterly report for updated cash runway metrics and operational performance data.
The combination of tax refund receipts and tax payable suggests the company is balancing product development investment with commercial revenue generation, a positive indicator for medtech firms transitioning from pure R&D operations to commercial scale.
Want the Next Healthcare Breakout in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with expert analysis. StockWire X delivers real-time alerts the moment market-moving announcements drop. Click the “Free Alerts” button to get ahead of the market.